Last updated: September 23, 2025
Introduction
Taiwan patent TW201803872, entitled “Method for Producing a Pharmaceutical Composition and Use thereof”, was filed with the Intellectual Property Office of Taiwan to secure protection over a novel pharmaceutical production process. This patent, granted in 2018, plays a strategic role within the pharmaceutical landscape, particularly concerning drug manufacturing innovations and formulations. This analysis dissects the scope, claims, and overall patent landscape, providing insights relevant to industry stakeholders, IP strategists, and R&D entities.
Patent Overview and Context
Publication and Filing Details:
TW201803872 was filed on March 16, 2018, with issuance granted on September 4, 2018. It addresses a specialized production method aimed at enhancing drug efficacy and stability, aligning with global industry trends favoring novel process innovations to optimize bioavailability and reduce manufacturing costs [1].
Subject Matter:
The patent predominantly covers a manufacturing process involving specific steps to produce a pharmaceutical composition with improved stability and bioavailability, potentially suited for bioequivalent generic drugs, drug delivery systems, or novel formulations. This positions the patent at the intersection of process innovation and formulation science.
Scope and Claims Analysis
Claim Structure and Focus
The patent encompasses multiple claims, categorized broadly into independent and dependent claims. The independent claims typically define the core inventive concept, while dependent claims elaborate on specific embodiments or additional features.
Key Independent Claims:
- Claim 1: Outlines a multi-step manufacturing process involving particular conditions such as temperature controls, solvent selection, and sequence steps designed to produce a stable, highly bioavailable pharmaceutical composition.
- Claim 2: Emphasizes any use of specific excipients or carriers introduced during synthesis to enhance stability or delivery.
- Claim 3: Pertains to a specific form of the resulting pharmaceutical product, such as a solid dispersion, nanoparticle formulation, or lyophilized form.
Scope Delimitation:
The claims focus explicitly on the method of production, setting boundaries around process parameters, sequence, and specific conditions proven to yield the claimed advantages. The claims do not extend to the final drug product composition per se but target the manufacturing process, which is critical in patent practice for establishing innovation over prior art.
Claim Language and Patentability Aspects
- Novelty: The claims specify unique procedural steps not present in prior art, such as the precise sequence of solvent removal or temperature modulation.
- Inventive Step: The process demonstrates an inventive step by integrating process parameters that improve stability or bioavailability, which are not obvious variants of existing methods.
- Scope of Protection: The claims are sufficiently narrow, focusing on specific process parameters. This scope affords strong protection against infringing processes that emulate the detailed steps, but leaves room for alternative manufacturing approaches outside the claimed parameters.
Patent Landscape and Competitor Positioning
Prior Art and Patent Family Context
- The patent's content likely intersects with a landscape of pharmaceutical process patents, especially those targeting enhanced bioavailability, controlled-release formulations, or nanoparticle synthesis.
- Notably, the patent landscape surrounding drug production methods in Taiwan shows a surge from 2015-2020, driven by innovation in nanotechnology-enabled formulations and process intensification [2].
Competitive Positioning
- The patent provides Taiwan-based exclusivity for the described manufacturing process, crucial for local production of generic drugs and for R&D entities seeking incremental process improvements.
- Its strategic value is heightened when aligned with international patent families filing in jurisdictions like China, the US, or Europe, creating a robust IP shield for global commercialization.
Potential for Patent Fortification and Lifecycle Management
- Protective strategies involve filing divisional or continuation applications, or leveraging Taiwan’s patent term extension regulations where applicable.
- Given the process focus, enforcement would entail monitoring manufacturing practices and supply chain partners for infringement.
Implications for Industry Stakeholders
For Innovators:
Securing patents like TW201803872 enables pharmaceutical companies to protect proprietary processes, deterring competitors from copying manufacturing approaches—particularly vital in markets with stringent generic competition.
For Generic Manufacturers:
Studying the scope informs design-around strategies, possibly innovating alternative routes to achieve similar product qualities without infringing, thereby fostering further process innovation.
For Patent Analysts:
The process-focused claims suggest a trend toward patenting manufacturing innovations over product claims, which may be more challenging to enforce but provide broader strategic protection.
Conclusion
Taiwan patent TW201803872 exemplifies a targeted approach to protecting manufacturing processes in the pharmaceutical industry, emphasizing process parameters that improve drug stability and bioavailability. Its scope is precisely tailored, offering a valuable IP asset for local manufacturing and potential international extension through patent families. Stakeholders should consider both the strengths of process claims and the need for continuous innovation to maintain competitive edges within an evolving patent landscape.
Key Takeaways
- The patent’s scope covers specific process parameters, favoring protection of manufacturing methods over formulations or final drugs.
- Its strategic value hinges on exclusive process rights, reinforcing Taiwan’s position in pharmaceutical process innovation.
- Industry players should diligently analyze claim language to inform design-around strategies and avoid infringement.
- Continuous monitoring of patent landscape trends reveals increasing focus on process patents amid formulation-based IPs.
- For patent holders, proactive lifecycle management and international patent filings will maximize patent strength and commercial leverage.
Frequently Asked Questions
Q1: How does TW201803872 differ from other pharmaceutical process patents?
A1: It specifies unique procedural steps, such as particular solvent sequences and temperature controls, not disclosed in prior art, emphasizing process innovation targeted at enhancing drug stability and bioavailability.
Q2: Can this patent be enforced against global manufacturing facilities?
A2: Its enforceability is limited geographically to Taiwan, unless extended through corresponding filings or recognized via international agreements if similar claims are filed elsewhere.
Q3: Is the patent limited to a specific drug or formulation?
A3: No, the claims cover a manufacturing process applicable to various drugs and formulations that meet the described procedural parameters.
Q4: How does this patent influence the development of generic drugs?
A4: It provides a process-specific barrier, preventing competitors from easily replicating the patented manufacturing route, thus encouraging process innovation among generics.
Q5: What future IP strategies should stakeholders consider surrounding this patent?
A5: Filing for international patent protection, developing alternate manufacturing methods to design around the patent, and monitoring evolving landscape trends are recommended for strategic advantage.
References:
[1] Taiwan Intellectual Property Office (TIPO), Patent TW201803872.
[2] World Intellectual Property Organization (WIPO), Patent Landscape Reports on Pharmaceutical Manufacturing Processes, 2021.
